ClinicalTrials.Veeva

Menu

A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants With Type 1 Diabetes

C

Carmot Therapeutics

Status and phase

Enrolling
Phase 1

Conditions

Type 1 Diabetes

Treatments

Drug: CT-868
Drug: Victoza
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT05794581
CT-868-005

Details and patient eligibility

About

This study will be conducted primarily to evaluate the effects of CT-868 on glucose homeostasis in participants with Type 1 Diabetes Mellitus.

Enrollment

24 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Female or male adults with Type 1 diabetes
  • Ages 18-65 years
  • Type 1 DM for at least 3 years
  • Using an insulin pump or multiple daily injections (MDI) for at least 3 months
  • BMI 25.0 - 35.0

Exclusion criteria

  • Significant medical history
  • Uncontrolled diabetes
  • History of surgical treatment for weight loss
  • History of malignancy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

24 participants in 3 patient groups, including a placebo group

CT-868
Experimental group
Description:
SC injection of CT-868 Intervention
Treatment:
Drug: CT-868
Placebo
Placebo Comparator group
Description:
SC injection of placebo matching CT-868 dose
Treatment:
Drug: Placebo
Victoza
Active Comparator group
Description:
SC injection of active comparator
Treatment:
Drug: Victoza

Trial contacts and locations

1

Loading...

Central trial contact

Michael Elliott

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems